Source comparison
Does BPC-157 Help Torn Rotator Cuff: Comparison of Repair Support Compounds
Researchers studying tendon repair often compare multiple peptides and growth factors to identify the most effective interventions. The table below contrasts BPC-157 with other compounds investigated for rotator cuff and tendon healing support. BPC-157 VEGF up
This comparison does not assign a generated winner or score.
- Researchers studying tendon repair often compare multiple peptides and growth factors to identify the most effective interventions. The table below contrasts BPC-157 with other compounds investigated for rotator cuff and tendon healing support.
- BPC-157
- VEGF upregulation, fibroblast migration, FAK pathway modulation
- Achilles tendon: 60% faster healing, improved tensile strength
- None for rotator cuff
- 200–500 mcg/kg (rodent equivalent)
- Strongest preclinical tendon data; zero human RCTs limit translation
- TB-500 (Thymosin Beta-4)
- Actin sequestration, cell migration, anti-inflammatory
- Cardiac and skeletal muscle repair; limited tendon-specific studies
- None for musculoskeletal injury
- 2–10 mg weekly (anecdotal human use)
- Broader tissue effects but less tendon-specific evidence than BPC-157
- PRP (Platelet-Rich Plasma)
- Growth factor delivery (PDGF, TGF-β, IGF-1)
- Mixed results; some studies show no benefit over placebo
- Multiple RCTs with inconsistent outcomes
- 3–6 mL per injection site
- FDA-approved for clinical use; evidence quality varies widely
- GH (Growth Hormone)
- IGF-1 stimulation, collagen synthesis
- Improves tendon thickness and stiffness in animal models
- Used off-label for tendon injuries; no high-quality RCTs
- 2–4 IU daily (human protocols)
- Systemic effects and cost limit practical use for isolated injuries
- Hyaluronic Acid
- Lubrication, matrix organisation, inflammation reduction
- Reduces adhesion formation post-surgery
- Some clinical use in rotator cuff repair; results modest
- 20–40 mg intra-articular
- Supports gliding mechanics but minimal effect on tendon tensile strength
- BPC-157 shows the most consistent tendon-specific effects in animal models, but the absence of human trials for rotator cuff injuries means its comparative efficacy remains theoretical. PRP is the only compound with FDA approval and direct clinical use in rotator cuff repair, though meta-analyses show high variability in outcomes depending on preparation method and injection timing.